DALLAS, July 17, 2009 (GLOBE NEWSWIRE) -- BeaconEquity.com announces an investment report featuring drug maker Avanir Pharmaceuticals (AVNR). The report includes financial, comparative and investment analyses, and pertinent industry information you need to know to make an educated investment decision.
The investment report on Avanir Pharmaceuticals (Nasdaq:AVNR) should be of particular interest to other pharmaceutical companies: Eli Lilly & Co. (NYSE:LLY), GlaxoSmithKline plc (NYSE:GSK), Amgen Inc. (Nasdaq:AMGN) and Biogen Idec Inc. (Nasdaq:BIIB).
It is available at: http://beaconequity.com/i/AVNR/
Get our alerts BEFORE the rest of the market. Follow us on Twitter: http://twitter.com/BeaconEquity
Avanir Pharmaceuticals engages in the development of therapeutic products for a variety of diseases primarily in the United States market. The Company recently focused its resources to address the central nervous systems and inflammatory diseases markets.
Read and post on Twitter and top Stock Message Boards for these stocks and more, all in real-time: http://www.BoardCentral.com/
In the report, the analyst notes:
"If ultimately approved by the U.S. Food and Drug Administration (FDA), the market for AVNR's drug candidate Zenvia could reach $500 million to more than $1 billion at its market saturation. Zenvia is in phase III clinical trials, with the prospects of reaching commercialization reaching approximately 90% following successful completion of this phase of development.
"The Company announced July 6, 2009, that Zenvia completed target enrollment in mid-March of phase III STAR clinical trials. Results of phase III STAR trail is anticipated to complete by September 2009."
To read the entire report visit: http://beaconequity.com/i/AVNR/
BeaconEquity.com is one of the industry's largest small-cap report providers. Beacon strives to provide a balanced view of many promising small-cap companies that would otherwise fall under the radar of the typical Wall Street investor. We provide investors with an excellent first step in their research and due diligence by providing daily trading ideas, and consolidating the public information available on them. For more information on Beacon Equity, please visit http://www.BeaconEquity.com
Beacon Equity Disclosure
DO NOT BASE ANY INVESTMENT DECISION UPON ANY MATERIALS FOUND ON THIS REPORT. We are not registered as a securities broker-dealer or an investment adviser either with the U.S. Securities and Exchange Commission (the "SEC") or with any state securities regulatory authority. We are neither licensed nor qualified to provide investment advice. Beacon Equity Research nor its affiliates have a beneficial interest in the mentioned company; nor have they received compensation of any kind for any of the companies listed in this communication. The information contained in our report is not an offer to buy or sell securities. We distribute opinions, comments and information free of charge exclusively to individuals who wish to receive them.